

Beltapharm S.P.A
Balance Sheet As At March 31, 2024

	Note No.	Amount in EUR	
		31-Mar-24	31-Mar-23
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment		2,309,203	2,641,590
(b) Capital work in progress		236,348	-
(c) Other intangible assets		13,385	15,535
(d) Other non-current assets	1	1,770	-
Total non-current assets		2,560,706	2,657,125
II Current assets			
(a) Inventories	2	1,694,376	1,076,511
(a) Financial assets			
(i) Trade receivables	3	1,356,966	3,522,862
(ii) Cash and cash equivalents	4	50,049	43,277
(c) Other Current assets	5	632,172	462,715
Total current assets		3,733,563	5,105,365
TOTAL ASSETS		6,294,269	7,762,490
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	6	1,456,000	1,456,000
(b) Reserves and Surplus	7	1,322,758	1,492,521
Total Equity		2,778,758	2,948,521
II Liabilities			
1 Non-current liabilities			
(a) Provisions	8	89,000	86,000
(b) Other non-current liabilities	9	208,400	203,200
Total non-current liabilities		297,400	289,200
II Current liabilities			
(a) Financial liabilities			
(i) Trade payables	10	1,157,043	1,668,312
(ii) Other financial liabilities	11	1,106,015	485,510
(b) Other current liabilities	12	955,053	2,370,947
Total current liabilities		3,218,111	4,524,769
TOTAL EQUITY AND LIABILITIES		6,294,269	7,762,490

Beltapharm S.P.A
Statement Of Profit And Loss For The Year Ended March 31, 2024

		Amount in EUR	
Note No.	Note No.	31-Mar-24	31-Mar-23
1	Revenue from operations	4,439,491	7,093,794
2	Total Revenue	<u>4,439,491</u>	<u>7,093,794</u>
3	Expenses		
	(a) Cost of materials consumed	2,281,025	3,146,559
	(a) Employee benefits expense	2,057,937	1,877,929
	(b) Finance costs	68,500	35,600
	(c) Depreciation and amortisation expense	245,400	243,396
	(d) Other expenses	2,128,069	1,649,270
	Total expenses	<u>6,780,931</u>	<u>6,952,754</u>
4	Profit / (Loss) before exceptional items and taxes	<u>(2,341,440)</u>	<u>141,040</u>
5	Exceptional Item	-	-
6	Profit / (Loss) before taxes	<u>(2,341,440)</u>	<u>141,040</u>
7	Tax Expense:		
	Total tax expenses	-	-
8	Profit / (Loss) for the year after tax	<u>(2,341,440)</u>	<u>141,040</u>

Beltapharm S.P.A
Notes forming part of financial statement

Note

No.

1 Other non current assets		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Deposits	1,770	-	
Total	1,770	-	

2 Inventories		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Raw Material	1,626,372	1,076,511	
Finished goods	68,004	-	
Total	1,694,376	1,076,511	

3 Trade receivables		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Unsecured			
Considered good	1,356,966	3,522,862	
Considered doubtful	532,000	280,000	
	1,888,966	3,802,862	
Less: Allowance for doubtful trade receivables	532,000	280,000	
Total	1,356,966	3,522,862	

4 Cash and cash equivalents		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Cash in hand	3,798	309	
Balances with banks:			
In current accounts	46,251	42,968	
Total	50,049	43,277	

5 Other current assets		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Unsecured, considered good			
Loans and advances to suppliers	440,172	222,049	
- VAT receivable	98,000	50,856	
Unbilled debtors	-	130,000	
Prepaid expenses	94,000	59,810	
Total	632,172	462,715	

6 Share capital		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Issued, subscribed and fully paid-up			
Equity share capital	1,456,000	1,456,000	
Total	1,456,000	1,456,000	

7 Reserves and surplus		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
General Reserve	244,067	244,067	
	244,067	244,067	
Capital Reserve	9,206,951	5,966,023	
	9,206,951	5,966,023	
Surplus in statement of profit and loss			
Opening balance	(5,786,820)	(4,858,609)	
Add: Profit / (Loss) for the year	(2,341,440)	141,040	
Closing balance	(8,128,260)	(4,717,569)	
Total	1,322,758	1,492,521	

8 Provisions (long term)		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Provisions (long term)	89,000	86,000	
Total	89,000	86,000	

9 Other non current liabilities		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Long term liabilities	208,400	203,200	
Total	208,400	203,200	

10 Trade payables		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Trade payable	1,157,043	1,668,312	
Total	1,157,043	1,668,312	

11 Other Current financial Liabilities		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Unsecured Bank loan	84,965	-	
- Statutory remittances	1,021,050	485,510	
Total	1,106,015	485,510.00	

12 Other current liabilities		Amount in EUR	
Particulars	31-Mar-24	31-Mar-23	
Advance received from customer	533,650	290,962	
Others	325,903	1,134,562	
Payable to employee (salary)	95,500	945,423	
Total	955,053	2,370,947	

Beltapharm S.P.A
Notes forming part of financial statement

Note

No.

13 Revenue from operations	Particulars	Note No.	Amount in EUR
		31-Mar-24	31-Mar-23
	Sale of Product	4,439,491	7,093,794
	Total	4,439,491	7,093,794

14 Cost of materials consumed	Particulars	31-Mar-24	31-Mar-23
	Opening stock	1,076,511	821,082
	Add: Purchases	2,898,890	3,401,988
	Closing stock	1,694,376	1,076,511
	Total	2,281,025	3,146,559

15 Employee benefit expenses	Particulars	Amount in EUR	
		31-Mar-24	31-Mar-23
	Salaries and wages	1,530,653	1,385,000
	Contribution to provident fund	457,826	405,000
	Staff Welfare	69,458	87,929
	Total	2,057,937	1,877,929

16 Finance cost	Particulars	Amount in EUR	
		31-Mar-24	31-Mar-23
	Bank charges	14,500	12,200
	Interest on working capital loans	31,958	23,400
	Finance charges	22,042	-
	Total	68,500	35,600

17 Other expenses	Particulars	Amount in EUR	
		31-Mar-24	31-Mar-23
	Power and fuel	196,100	151,500
	Consumables	418,875	312,178
	Labour Charges	50,675	-
	Freight and forwarding	26,000	132,600
	Rent	82,652	71,520
	Rates & taxes	67,641	80,493
	Repairs & Maintenance	286,753	205,955
	Insurance	61,000	59,000
	Books & Periodicals	1,850	1,600
	General expenses	80,145	114,530
	Printing & stationery	7,700	8,100
	Provision for doubtful debts	252,000	150,000
	Director Sitting Fess	127,780	128,503
	Conveyance & travelling	13,550	12,000
	Advertisement & Selling expenses	17,900	28,650
	Communication expenses	4,700	5,974
	Exchange fluctuation loss	16,300	(20,853)
	Waste Collection Charges	40,100	-
	Membership fees and subscription	3,933	-
	Legal expenses	-	5,520
	Professional fees & Legal fees	354,199	155,000
	Payment to Auditors - For Statutory Audit	-	47,000
	Miscellaneous Expense	18,216	-
	Total	2,128,069	1,649,270